Teen dies after viral TikTok challenge; what is 'dusting' and how it causes sudden sniffing death
'Dusting' is a viral trend in which individuals inhale cleaning spray for a brief moment of intoxication.
Some trends often go viral, with many unassuming children jumping on the bandwagon in an attempt to gain popularity. Earlier, trends like the ' Blue Whale Challenge ' also went viral, which led to many children causing harm to themselves.
This week, Renna O'Rourke, a 19-year-old living in the United States, succumbed to sudden sniffing death syndrome after she participated in the challenge. She ordered a computer cleaning spray to her home and inhaled its contents. After battling for four days in the ICU, she passed away — never having regained consciousness.
Speaking to local media, her parents are now trying to raise awareness of such dangerous challenges that young people often participate in.
Her father, while speaking to 12 News, said that she often said 'I'm gonna be famous, Dad'. "Unfortunately, this is not under the most optimal of circumstances," he added.
Her parents have urged other parents to keep an eye on their children's online activities. They have even asked other guardians to be mindful of the things children keep in their room and have access to.
What is sudden sniffing death syndrome?
Sudden sniffing death syndrome occurs when a fatal cardiac event takes place after inhaling some substances, often inhalants.
Inhalants are chemical vapours found in common household products like glue, paint thinners, cleaning fluids, and even some types of gas.
Sometimes, when a person inhales such substances, they can experience various effects which includes heart arrhythmia (irregular heartbeat), that can cause sudden cardiac arrest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
2 days ago
- Zawya
Five years after COVID, pharma shares languish in US policy limbo
MILAN - Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. 'ARMAGEDDON SCENARIO' Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. CATALYST NEEDED Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. "We're seeing companies go from unprofitable to very profitable," he said, citing Alnylam and Penumbra as examples he owns. "Historically, that's been a very good time to own healthcare stocks." LFG+ZEST's Conca, who favours U.S. names like Abbott , Edwards Lifesciences, and AbbVie, along with Sanofi and Recordati in Europe, said interest rate cuts could be a major catalyst. OUT OF THE WOODS? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. "The sector will adapt," wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come "at the cost of rebalancing its revenues and probably transforming its organisations." AstraZeneca, for example, has unveiled a $50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. "Healthcare has endured a lot of pain," said J.P. Morgan's Aliaga. "We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been." (Reporting by Danilo Masoni; Editing by Amanda Cooper and Jane Merriman)
Emirates 24/7
2 days ago
- Emirates 24/7
Study links 'forever chemicals' to increased risk of type 2 diabetes
Exposure to a class of synthetic chemicals known as per- and polyfluoroalkyl substances (PFAS), commonly referred to as "forever chemicals", may increase the risk of developing type 2 diabetes, according to a new study led by researchers at Mount Sinai. The findings were published in eBioMedicine. The team conducted a nested case-control study within BioMe, a large, electronic health record-linked research database comprising records of more than 70,000 study participants who have sought care at The Mount Sinai Hospital in New York City since 2007. Based on available data, the study analysed 180 people recently diagnosed with type 2 diabetes (T2D) and compared them to 180 similar individuals without diabetes. All participants were matched based on age, sex, and ancestry. Researchers used blood samples to analyse PFAS levels - a group of chemicals used in everything from nonstick cookware to stain-resistant furniture to waterproof clothing -and found that higher levels of PFAS were associated with a significantly greater risk of developing T2D in the future. Specifically, each increase in range of PFAS exposure was linked to a 31 percent increase in risk. The team also found that these associations could be due to metabolic irregularities in amino acid biosynthesis and drug metabolism, which may help explain how PFAS affect the body's ability to regulate blood sugar. Findings from this study underscore the importance of preventing PFAS exposures to promote public health and of advancing knowledge about potential mechanisms underlying the PFAS' impacts on human metabolism. Follow Emirates 24|7 on Google News.
Emirates 24/7
4 days ago
- Emirates 24/7
AstraZeneca plans to invest $50 billion in US by 2030
AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country, powering growth and delivering next-generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production. The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes expanding the R&D facility in Gaithersburg, Maryland; building a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continue manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas. Follow Emirates 24|7 on Google News.
